MedTrace Logo

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

NCT02678572 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2023-12-21

No results posted yet for this study

Summary

This study will evaluate patients who have melanoma that has spread from the eye to the liver: Patients in the study will be treated with Melphalan/HDS up to 6 total treatment, and will be followed until death. This study will evaluate the safety and effects of the treatment on how long patients live and how long it takes for the cancer to advance or respond to the treatment.

Conditions

  • Melanoma, Ocular

Interventions

COMBINATION_PRODUCT

Melphalan/HDS

Melphalan (3 mg/kg IBW) with Hepatic Device System (HDS)

Sponsors & Collaborators

  • IQVIA Biotech

    collaborator INDUSTRY

  • Delcath Systems Inc.

    lead INDUSTRY

Principal Investigators

  • Jonathan Zager, MD · Moffitt Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2023-05-18
Completion
2023-08-15

Countries

  • United States
  • Austria
  • Belgium
  • France
  • Germany
  • Italy
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02678572 on ClinicalTrials.gov